BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rippe M, Stefanello TF, Kaplum V, Britta EA, Garcia FP, Poirot R, Companhoni MVP, Nakamura CV, Szarpak-Jankowska A, Auzély-Velty R. Heparosan as a potential alternative to hyaluronic acid for the design of biopolymer-based nanovectors for anticancer therapy. Biomater Sci 2019;7:2850-60. [PMID: 31070204 DOI: 10.1039/c9bm00443b] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Coninx S, Kalot G, Godard A, Bodio E, Goze C, Sancey L, Auzély-Velty R. Tailored hyaluronic acid-based nanogels as theranostic boron delivery systems for boron neutron cancer therapy. Int J Pharm X 2022;4:100134. [PMID: 36304136 DOI: 10.1016/j.ijpx.2022.100134] [Reference Citation Analysis]
2 Yang W, Frickenstein AN, Sheth V, Holden A, Mettenbrink EM, Wang L, Woodward AA, Joo BS, Butterfield SK, Donahue ND, Green DE, Thomas AG, Harcourt T, Young H, Tang M, Malik ZA, Harrison RG, Mukherjee P, DeAngelis PL, Wilhelm S. Controlling Nanoparticle Uptake in Innate Immune Cells with Heparosan Polysaccharides. Nano Lett 2022. [PMID: 36048773 DOI: 10.1021/acs.nanolett.2c02226] [Reference Citation Analysis]
3 Yang W, Wang L, Fang M, Sheth V, Zhang Y, Holden AM, Donahue ND, Green DE, Frickenstein AN, Mettenbrink EM, Schwemley TA, Francek ER, Haddad M, Hossen MN, Mukherjee S, Wu S, DeAngelis PL, Wilhelm S. Nanoparticle Surface Engineering with Heparosan Polysaccharide Reduces Serum Protein Adsorption and Enhances Cellular Uptake. Nano Lett 2022. [PMID: 35166110 DOI: 10.1021/acs.nanolett.2c00349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
4 Sato W, Zajkowski T, Moser F, Adamala KP. Synthetic cells in biomedical applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;:e1761. [PMID: 34725945 DOI: 10.1002/wnan.1761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
5 Berdiaki A, Neagu M, Giatagana EM, Kuskov A, Tsatsakis AM, Tzanakakis GN, Nikitovic D. Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy. Biomolecules 2021;11:395. [PMID: 33800172 DOI: 10.3390/biom11030395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
6 Datta P, Fu L, Brodfuerer P, Dordick JS, Linhardt RJ. High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification. Appl Microbiol Biotechnol 2021;105:1051-62. [PMID: 33481068 DOI: 10.1007/s00253-020-11079-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
7 Rippe M, Michelas M, Putaux J, Fratzl M, Eslava GG, Dempsey NM, Auzély-velty R, Szarpak A. Synthesis and magnetic manipulation of hybrid nanobeads based on Fe3O4 nanoclusters and hyaluronic acid grafted with an ethylene glycol-based copolymer. Applied Surface Science 2020;510:145354. [DOI: 10.1016/j.apsusc.2020.145354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Zhang J, Yu H, Harris B, Zheng Y, Celik U, Na L, Faller R, Chen X, Haudenschild DR, Liu GY. New Means to Control Molecular Assembly. J Phys Chem C Nanomater Interfaces 2020;124:6405-12. [PMID: 33569091 DOI: 10.1021/acs.jpcc.9b11377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Gruber A, Navarro L, Klinger D. Reactive Precursor Particles as Synthetic Platform for the Generation of Functional Nanoparticles, Nanogels, and Microgels. Adv Mater Interfaces 2020;7:1901676. [DOI: 10.1002/admi.201901676] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
10 Rippe M, Cosenza V, Auzély-Velty R. Design of Soft Nanocarriers Combining Hyaluronic Acid with Another Functional Polymer for Cancer Therapy and Other Biomedical Applications. Pharmaceutics 2019;11:E338. [PMID: 31311150 DOI: 10.3390/pharmaceutics11070338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]